Cytomegalovirus (CMV)

Infectious Disease·MeSH: Renal Insufficiency

Prevalence

30.0 / 100K

7 drugs in development·6 companies·9 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
Prevymis	Merck & Co., Inc. (MRK)
t-spot.cmv	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Phase 2(2)

Drug	Company
triplex	Fortress Biotech Inc. (FBIO)
triplex	Fortress Biotech Inc. (FBIO)

Unknown(2)

Drug	Company
livtencity	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
livtencity	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 1/Phase 2(1)

Drug	Company
vbi-1501	VBI VACCINES INC/BC (VBIV)

BioSniper tracks 7 drugs in development for Cytomegalovirus (CMV) across 6 companies.

There are 9 clinical trials targeting Cytomegalovirus (CMV) tracked by BioSniper.

The estimated prevalence of Cytomegalovirus (CMV) is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.